Study #2019-1205
TELEHEART: Telotristat Ethyl in a Heart Biomarker Study
MD Anderson Study Status
Not Accepting
Treatment Agent
Telotristat Ethyl, Placebo Administration
Description
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and carcinoid heart disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Study phase:
Phase III
Physician name:
Cezar Iliescu
Department:
Cardiology
For general questions about clinical trials:
1-844-982-1565
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.